TIV-2

TIV-2 is a trial-specific designation for an inactivated trivalent split-virion influenza vaccine developed by GSK. It was utilized as a comparator arm in Phase III clinical trials (such as NCT01204671) to evaluate the immunogenicity, safety, and lot-to-lot consistency of GSK's quadrivalent seasonal influenza vaccines, including Fluarix Quadrivalent and FluLaval Quadrivalent. The TIV-2 formulation contains inactivated hemagglutinin (HA) antigens from three seasonal influenza virus strains: two influenza A subtypes (H1N1 and H3N2) and one influenza B lineage (Yamagata). Administered via intramuscular injection, the vaccine is designed to induce active immunity and the production of neutralizing antibodies to prevent seasonal influenza infection in adults.

Other names

trivalent influenza vaccine (B/Yamagata lineage)GSK trivalent influenza vaccineinactivated trivalent split-virion influenza vaccine